ArticlePloS one2019
Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Impact of Alcohol Use Discontinuation on Adipose Tissue Insulin Resistance Among Latino Patients With and Without Underlying Chronic Liver Disease.Research square · 2026Article
- Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations.JAMA network open · 2025Article
- Exploring the impact of graded alcohol use on atherogenic lipid profiles among Latinos with underlying chronic liver disease.Alcohol, clinical & experimental research · 2025Article
- Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis.Viruses · 2024Review
- Effects of comorbid conditions and prescribed chronic medications on the treatment plan for chronic hepatitis C infection: A cross-sectional retrospective study.Health science reports · 2024Article
- Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.Lancet regional health. Americas · 2024Article
- ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance.Scientific reports · 2023Article
- Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?Biomedicines · 2022Review
- Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.Alcoholism, clinical and experimental research · 2022Article
- Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Impact of HCV infection and ethnicity on incident type 2 diabetes: findings from a large population-based cohort in British Columbia.BMJ open diabetes research & care · 2021Article
- Macrophage Polarization and Its Role in Liver Disease.Frontiers in immunology · 2021Review
- Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury.Diagnostics (Basel, Switzerland) · 2020Article
- The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm.Journal of clinical medicine · 2020Review
- Advanced Glycation End Products as a Predictor of Diabetes Mellitus in Chronic Hepatitis C-Related Cirrhosis.Frontiers in medicine · 2020Article
- Metabolic Syndrome in HIV/HCV Co-infected Patients.Current treatment options in infectious diseases · 2019Article
- Management of Diabetes Mellitus in Patients with Chronic Liver Diseases.Journal of diabetes research · 2019Review
- REPLACING INSULIN WITH ANTI-VIRALS: A CLINICAL VIGNETTE ON DIABETES AND HCV TREATMENT.AACE clinical case reportsArticle
- A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatitis C virus (HCV) infection is associated with insulin resistance, which may lead to type 2 diabetes and its complications. Although HCV infects mainly hepatocytes, it may impair insulin sensitivity at the level of uninfected extrahepatic tissues (muscles and adipose tissue). The aim of this study was to assess whether an interferon-free, antiviral therapy may improve HCV-associated hepatic vs. peripheral insulin sensitivity.
methodsIn a single-arm exploratory trial, 17 non-diabetic, lean chronic hepatitis C patients without significant fibrosis were enrolled, and 12 completed the study. Patients were treated with a combination of sofosbuvir/ledipasvir and ribavirin for 12 weeks, and were submitted to a 2-step euglycemic hyperinsulinemic clamp with tracers, together with indirect calorimetry measurement, to measure insulin sensitivity before and after 6 weeks of antivirals. A panel of 27 metabolically active cytokines was analyzed at baseline and after therapy-induced viral suppression.
resultsClamp analysis performed in 12 patients who achieved complete viral suppression after 6 weeks of therapy showed a significant improvement of the peripheral insulin sensitivity (13.1% [4.6-36.7], p = 0.003), whereas no difference was observed neither in the endogenous glucose production, in lipolysis suppression nor in substrate oxidation. A distinct subset of hepatokines, potentially involved in liver-to-periphery crosstalk, was modified by the antiviral therapy.
conclusionPharmacological inhibition of HCV improves peripheral (but not hepatic) insulin sensitivity in non-diabetic, lean individuals with chronic hepatitis C without significant fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.